Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.55 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23232233 | 0.88 | LMNA (0.54) | SIGMAR1LMNAMAOAKDM4EMEN1 | |
| SCHEMBL3068577 | 0.86 | DRD2 (0.54) | SIGMAR1DRD2KDM4EMAPK1SLC6A2 | |
| SCHEMBL27573377 | 0.86 | SIGMAR1 (0.51) | SIGMAR1DRD2LMNAMAOAKDM4E | |
| Hydrochloric Acid SCHEMBL3066723 | 0.84 | DRD2 (0.53) | SIGMAR1DRD2KDM4EMAPK1SLC6A2 | |
| SCHEMBL11825786 | 0.83 | LMNA (0.62) | LMNAMAOAKDM4EMEN1KMT2A | |
| SCHEMBL10650155 | 0.81 | LMNA (0.47) | SIGMAR1LMNAMAOAKDM4EMEN1 | |
| SCHEMBL6730322 | 0.78 | DRD2 (0.47) | SIGMAR1DRD2LMNAMEN1KMT2A | |
| SCHEMBL654668 | 0.77 | DRD2 (0.59) | SIGMAR1DRD2LMNAMEN1KMT2A | |
| SCHEMBL22047755 | 0.76 | LMNA (0.44) | SIGMAR1LMNAMAOAKDM4EMEN1 | |
| SCHEMBL23325964 | 0.76 | PDE4B (0.53) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1714961-B1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2015-12-09 | — | — | EP | disclosed |
| US-7994196-B2 | Indazole compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-08-09 | — | — | US | disclosed |
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2007-07-26 | — | — | US | disclosed |
| EP-1714961-A1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2006-10-25 | — | — | EP | disclosed |
| EP-0861832-A1 | Novel tetrahydropyridine derivatives | SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) | 1998-09-02 | — | — | EP | disclosed |
| US-5410058-A | Exhibit high affinity and specificity to alpha receptors; useful in treating some psychoses | SHIONOGI & CO., LTD. (JP) | 1995-04-25 | — | — | US | disclosed |
| US-5362873-A | Tetrahydropyridine derivatives | SHIONOGI & CO., LTD. (JP) | 1994-11-08 | — | — | US | disclosed |
| US-5243051-A | Treatment of psychological disorders | SHIONIGI & CO., LTD. (JP) | 1993-09-07 | — | — | US | disclosed |
| US-5149817-A | Psychotropic agents | SHIONOGI & CO., LTD. (JP) | 1992-09-22 | — | — | US | disclosed |
| EP-0445701-A1 | Novel tetrahydropyridine derivatives | SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) | 1991-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | CYP3A5, CYP3A43, TP53 | SIGMAR1 3731/4885DRD2 3805/4885LMNA 3390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.